PE20081059A1 - Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk) - Google Patents
Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk)Info
- Publication number
- PE20081059A1 PE20081059A1 PE2007001218A PE2007001218A PE20081059A1 PE 20081059 A1 PE20081059 A1 PE 20081059A1 PE 2007001218 A PE2007001218 A PE 2007001218A PE 2007001218 A PE2007001218 A PE 2007001218A PE 20081059 A1 PE20081059 A1 PE 20081059A1
- Authority
- PE
- Peru
- Prior art keywords
- halo
- phenyl
- optionally substituted
- alcoxy
- pyrimidin
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title abstract 4
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- -1 PYRIDYLIDENE Chemical class 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical class CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 abstract 2
- QNKIGGHXVDYYKX-UHFFFAOYSA-N 2-(4-aminophenyl)-1-morpholin-4-ylethanone Chemical compound C1=CC(N)=CC=C1CC(=O)N1CCOCC1 QNKIGGHXVDYYKX-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE PIRIMIDINAS DE FORMULA (1) DONDE Z1 ES CR Y Z2 ES N O Z1 ES N Y Z2 ES CR; A ES FENILENO, PIRIDILIDENO, 2-OXO-1,2-DIHIDROPIRIDINILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS CON HALO, CN, NITRO, OXO, ENTRE OTROS SUSTITUYENTES; L ES ALQUILENO(C0-C4), O-ALQUILENO(C0-C4), ALQUILENO(C0-C4)(SO), ENTRE OTROS, OPCIONALMENTE SUSTIUIDOS CON HALO, CN, NITRO, OXO, ENTRE OTROS SUSTITUYENTES; G ES H, HALO, HIDROXI, ALCOXI(C1-C20), NITRO, ENTRE OTROS; R Y R1 SON CADA UNO H O ALQUILO(C1-C6); W ES FENILENO O PIRIDILIDENO OPCIONALMENTE SUSTITUIDOS CON ALQUILO(C1-C6), ALCOXI(C1-C6), HALO O HIDROXI; Q ES UN COMPUESTO DE FORMULA (i), (ii), ENTRE OTROS, DONDE R13, R14 Y R15 SON CADA UNO H, ALQUILO(C1-C6), HALOALQUILO(C1-C6), FENILO, ENTRE OTROS; R2 ES ARILO(C5-C6) O HETEROARILO DE 5 A 7 MIEMBROS OPCIONALMENTE SUSTITUIDOS CON HIDROXI, SULFONILO, HALO, ALCOXI(C1-C6), ENTRE OTROS SUSTITUYENTES. SON COMPUESTOS PREFERIDOS: 4-TER-BUTIL-N-(2-METIL-3-(2-(4-(2-MORFOLINO-2-OXOETIL)FENILAMINO)PIRIMIDIN-4-IL)FENIL)BENZAMIDA, 4-TER-BUTIL-N-(2-METIL-3-{2-[4-(MORFOLIN-4-CARBONIL)-FENILAMINO]-PIRIMIDIN-4-IL}-FENIL)-BENZAMIDA, {2-METIL-3-[2-(4-METILCARBAMOIL-FENILAMINO)-PIRIMIDIN-4-IL]-FENIL}-AMIDA DE ACIDO 4-TER-BUTILBENZOICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE LA TIROSINA QUINASA DE BRUTON (BTK) SIENDO UTILES EN EL TRATAMIENTO DE CANCER, LEUCEMIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84383606P | 2006-09-11 | 2006-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081059A1 true PE20081059A1 (es) | 2008-10-22 |
Family
ID=38884547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001218A PE20081059A1 (es) | 2006-09-11 | 2007-09-11 | Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk) |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20080125417A1 (es) |
| EP (1) | EP2069314A1 (es) |
| JP (1) | JP2010502749A (es) |
| KR (1) | KR20090061655A (es) |
| CN (1) | CN101605766A (es) |
| AR (1) | AR063946A1 (es) |
| AU (1) | AU2007296550A1 (es) |
| BR (1) | BRPI0716888A2 (es) |
| CA (1) | CA2661938A1 (es) |
| CL (1) | CL2007002641A1 (es) |
| IL (1) | IL197231A0 (es) |
| MX (1) | MX2009002648A (es) |
| NO (1) | NO20091423L (es) |
| PE (1) | PE20081059A1 (es) |
| RU (1) | RU2009113691A (es) |
| TW (1) | TW200829577A (es) |
| WO (1) | WO2008033834A1 (es) |
| ZA (1) | ZA200901593B (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009053269A1 (en) | 2007-10-23 | 2009-04-30 | F. Hoffmann-La Roche Ag | Novel kinase inhibitors |
| EP2297105B1 (en) * | 2008-05-06 | 2015-09-02 | Gilead Connecticut, Inc. | Substituted amides, method of making, and use as btk inhibitors |
| WO2012035039A1 (en) | 2010-09-15 | 2012-03-22 | F. Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
| JP2014503000A (ja) * | 2011-01-21 | 2014-02-06 | アッヴィ・インコーポレイテッド | キナーゼのピコリンアミド阻害剤 |
| CN103889962B (zh) * | 2011-04-01 | 2017-05-03 | 犹他大学研究基金会 | 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物 |
| KR20190011343A (ko) * | 2011-06-10 | 2019-02-01 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
| MX2014000338A (es) | 2011-07-08 | 2014-05-01 | Novartis Ag | Derivados de pirrolo-pirimidina novedoso. |
| US9782406B2 (en) | 2011-10-25 | 2017-10-10 | Peking University Shenzhen Graduate School | Kinase inhibitor and method for treatment of related diseases |
| CN103073508B (zh) * | 2011-10-25 | 2016-06-01 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
| AR088642A1 (es) | 2011-11-03 | 2014-06-25 | Genentech Inc | Compuestos de piperazina alquilados |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| CA2853967A1 (en) | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | 8-fluorophthalazin-1 (2h) -one compounds as inhibitors of btk activity |
| BR112014010391A2 (pt) | 2011-11-03 | 2017-04-18 | Hoffmann La Roche | composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica |
| EP2788347A1 (en) * | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| WO2013148603A1 (en) | 2012-03-27 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives as as btk inhibitors |
| US9013997B2 (en) * | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
| JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| CN104109127B (zh) * | 2013-04-19 | 2019-11-05 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
| MX367918B (es) | 2013-04-25 | 2019-09-11 | Beigene Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina quinasa. |
| HK1214820A1 (zh) | 2013-07-03 | 2016-08-05 | 豪夫迈．罗氏有限公司 | 雜芳基吡啶酮和氮雜-吡啶酮酰胺化合物 |
| RU2016112314A (ru) * | 2013-09-03 | 2017-10-05 | Карна Байосайенсиз, Инк. | Новое 2,6-диаминопиримидиновое производное |
| DK3044234T3 (da) | 2013-09-13 | 2020-05-18 | Beigene Switzerland Gmbh | Anti-PD1-antistoffer og anvendelse deraf som terapeutika og diagnostika |
| MX2016004030A (es) | 2013-09-30 | 2016-10-26 | Beijing Synercare Pharma Tech Co Ltd | Inhibidores sustituidos de nicotinamida de btk y su preparacion y uso en el tratamiento del cancer, inflamacion y enfermedad autoinmune. |
| US9512084B2 (en) * | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| US9260415B2 (en) | 2013-12-05 | 2016-02-16 | Genentech, Inc. | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| WO2015089337A1 (en) * | 2013-12-11 | 2015-06-18 | Biogen Idec Ma Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| WO2016079669A1 (en) * | 2014-11-19 | 2016-05-26 | Novartis Ag | Labeled amino pyrimidine derivatives |
| WO2017148837A1 (en) | 2016-02-29 | 2017-09-08 | F. Hoffmann-La Roche Ag | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| PL3436447T3 (pl) | 2016-03-31 | 2021-12-27 | Takeda Pharmaceutical Company Limited | Kompleksy triazolonu izochinolinylowego |
| NZ749997A (en) | 2016-07-05 | 2022-11-25 | Beigene Ltd | Combination of a pd-l antagonist and a raf inhibitor for treating cancer |
| SG11201901141WA (en) | 2016-08-16 | 2019-03-28 | Beigene Ltd | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| EP4353747A3 (en) | 2016-08-19 | 2024-06-26 | BeiGene Switzerland GmbH | Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer |
| US20190201409A1 (en) | 2016-09-19 | 2019-07-04 | Mei Pharma, Inc. | Combination therapy |
| WO2018137681A1 (en) | 2017-01-25 | 2018-08-02 | Beigene, Ltd. | Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof |
| JP2020514384A (ja) | 2017-03-24 | 2020-05-21 | ジェネンテック， インコーポレイテッド | 自己免疫及び炎症性疾患を治療する方法 |
| CA3066518A1 (en) | 2017-06-26 | 2019-01-03 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
| US11377449B2 (en) | 2017-08-12 | 2022-07-05 | Beigene, Ltd. | BTK inhibitors with improved dual selectivity |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| TWI856111B (zh) | 2019-06-10 | 2024-09-21 | 瑞士商百濟神州瑞士有限責任公司 | 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法 |
| JP2024540179A (ja) * | 2021-11-05 | 2024-10-31 | ユービックス セラピューティクス インコーポレイテッド | Ｂｔｋタンパク質分解活性を有する化合物及びその医薬用途 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0014022D0 (en) * | 2000-06-08 | 2000-08-02 | Novartis Ag | Organic compounds |
| US7429599B2 (en) * | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| GB0103926D0 (en) * | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| EP2172460A1 (en) * | 2002-11-01 | 2010-04-07 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
| US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| CA2533474A1 (en) * | 2003-07-30 | 2005-02-10 | Shudong Wang | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| CA2539339A1 (en) * | 2003-09-30 | 2005-04-14 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| PE20060582A1 (es) * | 2004-10-13 | 2006-08-17 | Wyeth Corp | Analogos de anilino-pirimidina |
| KR20070086600A (ko) * | 2004-11-23 | 2007-08-27 | 셀진 코포레이션 | Ｃｎｓ 손상의 치료를 위한 ｊｎｋ 억제제 |
| EA200870217A1 (ru) * | 2006-01-30 | 2009-02-27 | Экселиксис, Инк. | 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции |
-
2007
- 2007-09-10 AR ARP070103990A patent/AR063946A1/es unknown
- 2007-09-11 CA CA002661938A patent/CA2661938A1/en not_active Abandoned
- 2007-09-11 MX MX2009002648A patent/MX2009002648A/es not_active Application Discontinuation
- 2007-09-11 BR BRPI0716888-8A patent/BRPI0716888A2/pt not_active Application Discontinuation
- 2007-09-11 CN CNA2007800418203A patent/CN101605766A/zh active Pending
- 2007-09-11 PE PE2007001218A patent/PE20081059A1/es not_active Application Discontinuation
- 2007-09-11 RU RU2009113691/04A patent/RU2009113691A/ru not_active Application Discontinuation
- 2007-09-11 KR KR1020097007472A patent/KR20090061655A/ko not_active Withdrawn
- 2007-09-11 CL CL200702641A patent/CL2007002641A1/es unknown
- 2007-09-11 AU AU2007296550A patent/AU2007296550A1/en not_active Abandoned
- 2007-09-11 TW TW096133933A patent/TW200829577A/zh unknown
- 2007-09-11 US US11/853,488 patent/US20080125417A1/en not_active Abandoned
- 2007-09-11 EP EP07814805A patent/EP2069314A1/en not_active Withdrawn
- 2007-09-11 JP JP2009527622A patent/JP2010502749A/ja active Pending
- 2007-09-11 WO PCT/US2007/078154 patent/WO2008033834A1/en active Application Filing
-
2009
- 2009-02-24 IL IL197231A patent/IL197231A0/en unknown
- 2009-03-05 ZA ZA200901593A patent/ZA200901593B/xx unknown
- 2009-04-07 NO NO20091423A patent/NO20091423L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007296550A1 (en) | 2008-03-20 |
| JP2010502749A (ja) | 2010-01-28 |
| IL197231A0 (en) | 2009-12-24 |
| ZA200901593B (en) | 2010-03-31 |
| KR20090061655A (ko) | 2009-06-16 |
| CL2007002641A1 (es) | 2008-06-20 |
| WO2008033834A1 (en) | 2008-03-20 |
| TW200829577A (en) | 2008-07-16 |
| CN101605766A (zh) | 2009-12-16 |
| AR063946A1 (es) | 2009-03-04 |
| EP2069314A1 (en) | 2009-06-17 |
| CA2661938A1 (en) | 2008-03-20 |
| NO20091423L (no) | 2009-06-10 |
| BRPI0716888A2 (pt) | 2013-10-22 |
| US20080125417A1 (en) | 2008-05-29 |
| RU2009113691A (ru) | 2010-10-20 |
| MX2009002648A (es) | 2009-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081059A1 (es) | Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk) | |
| PE20050018A1 (es) | Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b) | |
| PE20070136A1 (es) | COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1 | |
| NO20072605L (no) | Nytt antranilinsyrederivat eller et salt derav | |
| PE20091656A1 (es) | Compuestos heterociclicos como inhibidores de la cinasa raf | |
| PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20061357A1 (es) | COMPUESTOS DERIVADOS DE AMINOSULFONILO COMO INHIBIDORES DE LA 11-ß-HSD-1 | |
| NO20071642L (no) | N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger | |
| PE20121153A1 (es) | Quinazolinas como inhibidores de los canales ionicos de potasio | |
| NZ595087A (en) | Novel amino azaheterocyclic carboxamides | |
| PE20091840A1 (es) | Inhibidores de piridilo de la senalizacion hedgehog | |
| EP1590344A2 (en) | Anti-cancer medicaments | |
| DE602005023343D1 (de) | Pyrimidinderivate als gpcr-agonisten | |
| PE20120229A1 (es) | Compuestos heterociclicos como inhibidores de proteasa aspartica | |
| PE20090815A1 (es) | Compuesto de amida | |
| ATE537169T1 (de) | Piperidin- und piperazinderivate als p2x3- antagonisten | |
| PE20141375A1 (es) | Activadores de glucoquinasa | |
| RU2010142937A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ | |
| PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
| RU2008129723A (ru) | Ингибиторы ccr9 активности | |
| RU2008130878A (ru) | Описание терапевтического средства против диабета | |
| PE20120937A1 (es) | Compuestos derivados de quinolina y quinoxalina como agentes antivirales | |
| AR053895A1 (es) | Aminopirimidinas como moduladores de quinasas | |
| PE20070212A1 (es) | Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen | |
| TN2010000173A1 (fr) | Antagonistes de cgrp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |